IR@PKUHSC  > 北京大学精神卫生研究所
学科主题精神卫生
Open-label, dose-titration tolerability study of atomoxetine hydrochloride in Korean, Chinese, and Taiwanese adults with attention-deficit/hyperactivity disorder
Takahashi, Michihiro1,2; Goto, Taro1; Takita, Yasushi1; Chung, Sang-Keun3; Wang, Yufeng4; Gau, Susan Shur-Fen5,6
关键词adult atomoxetine attention-deficit hyperactivity disorder Chinese Korean Taiwanese
刊名ASIA-PACIFIC PSYCHIATRY
2014-03-01
DOI10.1111/j.1758-5872.2012.00204.x
6期:1页:62-70
收录类别SCI ; SSCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Psychiatry
资助者Eli Lilly Japan K.K. ; Eli Lilly Japan K.K.
研究领域[WOS]Psychiatry
关键词[WOS]ONCE-DAILY ATOMOXETINE ; DEFICIT/HYPERACTIVITY DISORDER ; DOUBLE-BLIND ; ADHD SYMPTOMS ; ADOLESCENTS ; CHILDREN ; TRIAL ; ASSOCIATION ; PREVALENCE ; SLEEP
英文摘要

IntroductionThe primary objective of this study was to assess the overall safety and tolerability of atomoxetine in Korean, Chinese, and Taiwanese adults with attention-deficit/hyperactivity disorder (ADHD).

MethodsA total of 44 patients aged 18 years who met the Conners′ Adult ADHD Diagnostic Interview for DSM-IV diagnostic criteria for ADHD were enrolled from China, Korea, and Taiwan. In this open-label, dose-escalation study, patients received atomoxetine orally once daily over a period of eight weeks, starting at 40mg/day (one week) up to a maximum dosage of 120mg/day. Tolerability was evaluated by rate of discontinuation due to adverse events. Safety was assessed by recording all adverse events, laboratory tests, vital signs, and electrocardiograms. ADHD symptoms were evaluated by the Conners′ Adult ADHD Rating Scale-Investigator Rated: Screening Version (CAARS-Inv:SV) for efficacy assessment.

ResultsThirty-four patients (77.3%) completed the study. Atomoxetine was well tolerated with a discontinuation rate of 2.3% (1/44) due to adverse events. The most commonly reported adverse events were nausea, dizziness, and somnolence. The mean change from baseline to endpoint in CAARS-Inv:SV total ADHD symptom score was -12.5 (P<0.001). A significant reduction in the CAARS-Inv:SV subscales (inattentive, hyperactive/impulsive, and ADHD index score, P<0.001) was observed.

DiscussionThis is the first atomoxetine clinical trial in adult patients with ADHD in China, Korea, and Taiwan. Atomoxetine was well tolerated in doses of up to 120mg/day with no unknown safety concerns.

语种英语
资助者Eli Lilly Japan K.K. ; Eli Lilly Japan K.K.
WOS记录号WOS:000331552400008
Citation statistics
Cited Times:10[WOS]   [WOS Record]     [Related Records in WOS]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/59709
Collection北京大学精神卫生研究所
作者单位1.Terauchi Takahashi Psychiat Clin, Ashiya, Japan
2.Natl Taiwan Univ, Coll Med, Taipei 10764, Taiwan
3.Eli Lilly Japan KK, Lilly Res Labs Japan, Kobe, Hyogo 6510086, Japan
4.Chonbuk Natl Univ, Sch Med, Dept Psychiat, Jeonju, South Korea
5.Peking Univ, Inst Mental Hlth, Hosp Affiliated 6, Dept Child Psychiat, Beijing 100871, Peoples R China
6.Natl Taiwan Univ Hosp, Dept Psychiat, Taipei, Taiwan
Recommended Citation
GB/T 7714
Takahashi, Michihiro,Goto, Taro,Takita, Yasushi,et al. Open-label, dose-titration tolerability study of atomoxetine hydrochloride in Korean, Chinese, and Taiwanese adults with attention-deficit/hyperactivity disorder[J]. ASIA-PACIFIC PSYCHIATRY,2014,6(1):62-70.
APA Takahashi, Michihiro,Goto, Taro,Takita, Yasushi,Chung, Sang-Keun,Wang, Yufeng,&Gau, Susan Shur-Fen.(2014).Open-label, dose-titration tolerability study of atomoxetine hydrochloride in Korean, Chinese, and Taiwanese adults with attention-deficit/hyperactivity disorder.ASIA-PACIFIC PSYCHIATRY,6(1),62-70.
MLA Takahashi, Michihiro,et al."Open-label, dose-titration tolerability study of atomoxetine hydrochloride in Korean, Chinese, and Taiwanese adults with attention-deficit/hyperactivity disorder".ASIA-PACIFIC PSYCHIATRY 6.1(2014):62-70.
Files in This Item:
There are no files associated with this item.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
谷歌学术
谷歌学术Similar articles in
[Takahashi, Michihiro]'s Articles
[Goto, Taro]'s Articles
[Takita, Yasushi]'s Articles
百度学术
百度学术Similar articles in
[Takahashi, Michihiro]'s Articles
[Goto, Taro]'s Articles
[Takita, Yasushi]'s Articles
必应学术
必应学术Similar articles in
[Takahashi, Michihiro]'s Articles
[Goto, Taro]'s Articles
[Takita, Yasushi]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.